525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
| Autor: | Makker, V., Colombo, N., Casado Herraez, A., Monk, B.J., Mackay, H., Santin, A.D., Miller, D.S., Moore, R.G., Baron-Hay, S.E., Ray-Coquard, I.L., Shapira-Frommer, R., Ushijima, K., Yonemori, K., Kim, Y.M., Guerra Alia, E.M., Sanli, U.A., Huang, J., McKenzie, J., Barresi, G., Lorusso, D. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S785-S786 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|